Life Sciences Archives - Page 16 of 17 - EverGlade

Life Sciences

Female scientist in a hazmat suit researching WMD-related security challenges

DTRA BAA Weapons of Mass Destruction Amendment

Leave a Comment / All Posts, DTRA, Life Sciences / By

DTRA BAA Outlines New Opportunity to Identify and Counter Weapons of Mass Destruction (WMD) through the Strategic Trends Research Initiative The Defense Threat Reduction Agency (DTRA) has amended its Broad Agency Announcement (BAA) to offer new funding opportunities through the Strategic Trends Research Initiative (STRI) for identifying and countering Weapons of Mass Destruction (WMD), defined

DTRA BAA Weapons of Mass Destruction Amendment Read More »

Scientist with test tubes for NIAID Funding Guide

A Guide to NIAID Funding

Leave a Comment / All Posts, Guides, Life Sciences, NIAID / By

A Guide to NIAID Funding: Application Process, Financial and Technical Requirements The National Institute of Allergy and Infectious Diseases (NIAID) is a part of the U.S. National Institutes of Health (NIH), focusing on research related to infectious, immunologic, and allergic diseases. Securing NIAID funding can be a significant milestone for researchers and organizations in these

A Guide to NIAID Funding Read More »

Female scientist with vile and PPE for DTRA Funding Guide

A Guide to DTRA Funding

Leave a Comment / All Posts, DTRA, Guides, Life Sciences / By

A Guide to DTRA Funding: Application Process, Financial and Technical Requirements The Defense Threat Reduction Agency (DTRA) is a U.S. Department of Defense (DoD) agency that focuses on countering weapons of mass destruction. DTRA offers numerous funding opportunities for research and development projects, but navigating the technical and financial requirements can be challenging. This guide

A Guide to DTRA Funding Read More »

Laser tumor removal

Launch of New ARPA-H Funding Opportunity for Novel Technologies for More Precise and Accurate Cancer Tumor Removal

Leave a Comment / All Posts, ARPA-H, Life Sciences / By

The Biden Cancer Moonshot has announced a pioneering program under the Advanced Research Projects Agency for Health (ARPA-H) to develop innovative technologies to enhance the precision and accuracy of tumor removal in cancer surgeries. Precision Surgical Interventions (PSI) The new Precision Surgical Interventions (PSI) program is ARPA-H’s first initiative aimed at cancer and represents a

Launch of New ARPA-H Funding Opportunity for Novel Technologies for More Precise and Accurate Cancer Tumor Removal Read More »

Antibodies attacking virus cell for BARDA Funding Guide

A Guide to BARDA Funding

Leave a Comment / All Posts, BARDA, Guides, Life Sciences / By

A Guide to BARDA Funding: Application Process, Financial and Technical Requirements A Comprehensive Guide to BARDA Funding The Biomedical Advanced Research and Development Authority, commonly known as BARDA, has played a pivotal role in safeguarding public health in the United States and beyond. Since its inception, BARDA has bolstered the country’s preparedness and response capabilities

A Guide to BARDA Funding Read More »

Construction workers reviewing building layout for ASPR Funding Guide

A Guide to ASPR IBx Funding

Leave a Comment / All Posts, Guides, Life Sciences / By

A Guide to ASPR IBx Funding: Application Process, Financial and Technical Requirements The Assistant Secretary for Preparedness and Response (ASPR) Industrial Base Expansion (IBx) team is agroup within the U.S. Department of Health and Human Services that provides funding opportunities aimed at strengthening public health and medical supply chains and addressing concerns regarding domestic manufacturing

A Guide to ASPR IBx Funding Read More »

Woman in front of a 3d digital chest xray

New Request for Information by ARPA-H for FDA

Leave a Comment / All Posts, ARPA-H, Life Sciences / By

New Request for Information (RFI) Released by the Advanced Research Projects Agency for Health (ARPA-H) Solicits Ideas for Engaging with the FDA on Regulatory Strategies for Health Innovations ARPA-H, or the Advanced Research Projects Agency for Health, is a new agency within the National Institutes of Health (NIH) that aims to accelerate the development of

New Request for Information by ARPA-H for FDA Read More »

Vaccine Research Lap with computer showing mrna diagrams

Release of New Funding Opportunities for the Development of Vaccines and Therapeutics

Leave a Comment / Life Sciences / By

EverGlade Funding Alert: Biden Administration Announces Launch of Successor Program to Operation Warp Speed Accompanied by the Release of New Funding Opportunities for the Development of Vaccines and Therapeutics Project Next Gen Project Next Gen is a new program launched by the Biden administration aimed at accelerating the development of new coronavirus vaccines and treatments.

Release of New Funding Opportunities for the Development of Vaccines and Therapeutics Read More »

Scientist researching vaccine for biodefense

NIAID BAA Outlines New Funding Opportunities for the Development of Vaccines, Therapeutics, and Diagnostics

Leave a Comment / All Posts, Life Sciences / By

The National Institute of Allergy and Infectious Diseases (“NIAID”) recently published Broad Agency Announcement (‘BAA”) No. HHS-NIH-NIAID-BAA2023-1, which provides funding opportunities for the advancement of promising candidate vaccines, therapeutics, and diagnostics for Biodefense, Emerging Infectious Diseases, and Pandemic Preparedness. Four Areas for NIAID Funding 1. Research Area 001 – Development of Vaccine Candidates for Biodefense

NIAID BAA Outlines New Funding Opportunities for the Development of Vaccines, Therapeutics, and Diagnostics Read More »

A New Valley of Death? by Eric Jia-Sobota

Leave a Comment / Life Sciences / By

It seems that there may be a new Valley of Death on the horizon of COVID therapeutic development. Earlier this month (9 JUL) NIAID posted a Funding Opportunities Announcement soliciting proposals related to COVID therapeutic development through their Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern program (RFA-AI-21-050: Antiviral Drug Discovery (AViDD) Centers

A New Valley of Death? by Eric Jia-Sobota Read More »

COVID-19 Antiviral Therapeutics Procurement by Eric Jia-Sobota

Leave a Comment / Life Sciences / By

Earlier this month the Army Contracting Command published an amendment to solicitation W911QY-20-S-C001 related to Area of Interest 5, oral antiviral therapeutics. This is a procurement solicitation and specifically the USG is looking for direct-acting antivirals for COVID-19 high-risk patients. Successful offerors will be able to deliver 500,000 treatment courses of the anti-viral within eight

COVID-19 Antiviral Therapeutics Procurement by Eric Jia-Sobota Read More »

New Opportunity for COVID Therapeutics by Eric Jia-Sobota

Leave a Comment / Life Sciences / By

For the past 18 months companies have been confused and frustrated by the shifting USG policies regarding the development of therapeutics as part of the COVID-19 response. BARDA was back and forth as parts of the BAA were suspended, unsuspended, and resuspended. The American rescue Plan legislation was passed about six months ago and although

New Opportunity for COVID Therapeutics by Eric Jia-Sobota Read More »

Scroll to Top